Loading stock data…
Syndax Pharmaceuticals (SNDX)
$21.78+0.47 (+2.21%)
After Hours$21.56-0.22 (-1.00%)· Last close Jun 29
Syndax Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, develops therapies for the treatment of cancer.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Syndax Pharmaceuticals, Inc. in the Healthcare sector is trading at $21.78 with a market capitalization of $1.6B. Wall Street consensus targets $39.00 (12 analysts), implying a +79.1% move over the next 12 months. The stock is currently 15% below its 52-week high of $25.59, remaining 11.0% above its 200-day moving average. On fundamentals, Piotroski 1/9 flags weak fundamentals, Altman Z in the distress zone. The Whystock Score of 70/100 reflects bullish alignment across trend, valuation and analyst targets.
Ecosystem Influences
Sell-side targets imply +79.1% upside over 12 months
Long-term trend bullish (price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Quarterly Financials
| Metric (USD) | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 |
|---|---|---|---|---|---|
| Total Revenue | $64.86M↓ | $68.73M↑ | $45.87M↑ | $37.96M↑ | $20.04M |
| Gross Profit | $62.23M↓ | $66.02M↑ | $43.77M↑ | $36.68M↑ | $19.16M |
| Operating Income | -$34.20M↑ | -$62.55M↓ | -$57.43M↑ | -$69.35M↑ | -$83.76M |
| Net Income | -$42.67M↑ | -$68.01M↓ | -$60.72M↑ | -$71.85M↑ | -$84.85M |
Peer Comparison
JNJUNHPFE
Fundamentals
Syndax Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, develops therapies for the treatment of cancer. Its lead product candidate includes Revuforj (revumenib), a menin inhibitor for the treatment of relapsed or refractory R/R ac...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$1.62B
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
-
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-584.42%
Volume
Today's trading volume
4.23M
Recent News
3 Biotech Takeover Targets Wall Street Is Watching After the Apogee Deal
Big pharma’s appetite for clinical-stage biotech is back. The pending acquisition of Apogee Therapeutics by AbbVie (NYSE: ABBV), targeting an atopic dermatitis and immunology developer, has reignited a question every healthcare portfolio manager is asking: who will be next? The Apogee setup is the template buyers are chasing: late-stage clinical data, a meaningful addressable market, ... 3 Biotech Takeover Targets Wall Street Is Watching After the Apogee Deal
Syndax Pharmaceuticals (SNDX) Is Up 5.2% After Strong All-Oral Revuforj SAVE Trial Data - What's Changed
On 11 June 2026, Syndax Pharmaceuticals reported Phase 1/2 SAVE trial data showing high response and remission rates for an all-oral Revuforj-based regimen in heavily pretreated relapsed or refractory acute myeloid leukemia, published in the Journal of Clinical Oncology and presented at the European Hematology Association Congress. A key insight is that this regimen uses the FDA-approved monotherapy dose of Revuforj in combination and produced deep measurable residual disease negativity...
Assessing Whether Syndax Pharmaceuticals (SNDX) Looks Undervalued After Recent Share Price Weakness
Syndax Pharmaceuticals (SNDX): recent move and context Syndax Pharmaceuticals (SNDX) has drawn fresh attention after recent trading, with the stock last closing at US$19.94. Recent returns are mixed, including a gain over the past year and a decline year to date. Over the past month the stock is down about 7%, while performance over the past 3 months is roughly flat. That backdrop sets the stage for looking more closely at the company’s fundamentals. See our latest analysis for Syndax...
Why Syndax Pharmaceuticals (SNDX) is One of the Best Small Cap Stocks to Buy for 10x Potential
Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) is one of the best small cap stocks to buy for 10x potential. On May 4, Stifel lifted the price target on Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) to $46 from $45, reaffirming a Buy rating on the shares. It told investors that although modest consensus misses on Revuforj and Niktimvo sales are […]
Syndax (SNDX) Narrows Losses as Revuforj and Niktimvo Gain Traction - What’s Really Shifting?
Syndax Pharmaceuticals reported past first-quarter 2026 results, with revenue rising to US$64.86 million from US$20.04 million and net loss improving to US$42.67 million from US$84.85 million a year earlier. The quarter underscored growing commercial traction for Revuforj and Niktimvo, as higher product and collaboration revenue helped narrow per-share losses despite ongoing investment. Next, we’ll assess how this sharper revenue growth and reduced net loss shape Syndax Pharmaceuticals’...